Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOOSTER: Bevacizumab plus paclitaxel optimization with maintenance endocrine therapy in ER-positive HER2-negative metastatic breast cancer
jRCTs021180026Phase 2Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Jan 2014
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bevacizumab and paclitaxel in breast cancer (2 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Time to failure of strategy (TFS). Started Jan 2014; status: completed.
02
Drugs
bevacizumabpaclitaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCTs021180026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs021180026.